文献速递呼吸危重症与机械通气

已建立ARDS后的通气:提高预测力的临床前模型框架

Ventilation following established ARDS: a preclinical model framework to improve predictive power.
PubMed 文献 · Thorax · 2019-07-05

该研究在小鼠中先以鼻内脂多糖诱导肺损伤,在损伤高峰(48小时)叠加中等潮气量通气(20 mL/kg)以模拟二次呼吸机相关肺损伤,并测试特布他林与抗TNF受体1抗体。特布他林在非损伤动物中减轻VILI,但在已损伤肺中无效,模拟其临床无效性;抗TNF受体1抗体在已损伤肺中减轻二次VILI,表明模型可治疗。作者建议采用该框架,以减少最终无效药物进入临床试验。

要点

  • 在LPS肺损伤高峰叠加20 mL/kg通气可诱导二次VILI。
  • 特布他林在非损伤动物中减轻VILI,但在已损伤肺中无效。
  • 抗TNF受体1抗体在已损伤肺中减轻二次VILI,提示模型可治疗。

核心结论

  • 在已建立肺损伤的小鼠中叠加通气可模拟临床无效药物的反应,并识别在已损伤肺中仍有效的干预。
  • 建议采用该框架,以先前临床失败药物为对照,减少最终无效药物进入临床试验。

研究设计与样本

  • 小鼠鼻内脂多糖诱导肺损伤,在损伤高峰(48小时)经气管内给予特布他林或抗TNF受体1抗体,并以20 mL/kg潮气量通气诱导二次VILI。

主要发现

  • LPS损伤小鼠以20 mL/kg通气较8 mL/kg低潮气量通气加重损伤。
  • 特布他林在非LPS处理动物中减轻VILI,但在已损伤小鼠中不能减轻VILI。
  • 抗TNF受体1抗体在已损伤肺中减轻二次VILI。

关键数值与推荐

  • LPS损伤在48小时达高峰,依据低氧血症和力学受损等临床相关参数判定。
  • 中等潮气量为20 mL/kg,低潮气量为8 mL/kg。

临床怎么用

  • 临床前药物评价应在已建立损伤并叠加通气的模型中,与临床失败药物并列比较。
  • 进入试验前,新药应至少优于既往临床失败药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in understanding the pathophysiology of acute respiratory distress syndrome, effective pharmacological interventions have proven elusive. We believe this is a consequence of existing preclinical models being designed primarily to explore biological pathways, rather than predict treatment effects. Here, we describe a mouse model in which both therapeutic intervention and ventilation were superimposed onto existing injury and explored the impact of β-agonist treatment, which is effective in simple models but not clinically. METHODS: Mice had lung injury induced by intranasal lipopolysaccharide (LPS), which peaked at 48 hours post-LPS based on clinically relevant parameters including hypoxaemia and impaired mechanics. At this peak of injury, mice were treated intratracheally with either terbutaline or tumour necrosis factor (TNF) receptor 1-targeting domain antibody, and ventilated with moderate tidal volume (20 mL/kg) to induce secondary ventilator-induced lung injury (VILI). RESULTS: Ventilation of LPS-injured mice at 20 mL/kg exacerbated injury compared with low tidal volume (8 mL/kg). While terbutaline attenuated VILI within non-LPS-treated animals, it was ineffective to reduce VILI in pre-injured mice, mimicking its lack of clinical efficacy. In contrast, anti-TNF receptor 1 antibody attenuated secondary VILI within pre-injured lungs, indicating that the model was treatable. CONCLUSIONS: We propose adoption of a practical framework like that described here to reduce the number of ultimately ineffective drugs reaching clinical trials. Novel targets should be evaluated alongside interventions which have been previously tested clinically, using models that recapitulate the (lack of) clinical efficacy. Within such a framework, outperforming a failed pharmacologic should be a prerequisite for drugs entering trials.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Oakley C, Koh M, Baldi R, et al. Ventilation following established ARDS: a preclinical model framework to improve predictive power. Thorax. 2019. PMID: 31278170. doi:10.1136/thoraxjnl-2019-213460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。